Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease

NCT00566501 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00566501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00566501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 14, 2007
Completion date
April 1, 2010
Enrollment
915 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease